CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen.
Thibault, Gilles; Paintaud, Gilles; Legendre, Christophe; Merville, Pierre; Coulon, Maxime; Chasseuil, Elodie; Ternant, David; Rostaing, Lionel; Durrbach, Antoine; Di Giambattista, Fabienne; Büchler, Matthias; Lebranchu, Yvon.
; 29(2): 184-95, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26369526
The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients.
Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.
Belatacept for kidney transplant recipients.
Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
Posterior reversible encephalopathy syndrome after kidney transplantation in pediatric recipients: Two cases.
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study.
IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.
The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.
Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.